Esophageal Cancer Clinical Trial
A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer
The purpose of this research is to collect surgical drain fluid and blood from patients who have undergone surgery for gastric or esophageal cancer, and to analyze the fluid and blood using a variety of laboratory techniques for molecular markers capable of predicting response to immunotherapy.
Patients undergoing esophagectomy or gastrectomy for gastroesophageal cancer.
Adult males and females at least 18 years of age
Ability to complete testing in the protocol and attend study visits
Able and willing to consent to protocol
Adequate organ function Absolute Neutrophil Count (ANC) ≥1.5 x 103/μL Platelets ≥100 x 103/μL Hemoglobin >9.0 g/dL Total Bilirubin (= 2.0 mg/dl at time of Y90 radioembolization) AST/ALT ≤5 x upper limit of normal Albumin >3 g/dL Creatinine ≤1.5 mg/dL
Female patients who are pregnant or breast-feeding
Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
Life-threatening intercurrent illness
Anticipated poor compliance
Prisoners or subjects who are involuntarily incarcerated
Persons with decisional incapacity/cognitive impairment
Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study
Subject is enrolled in a separate interventional clinical trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.